Webinar Overview

Acute lung injury (ALI), or acute respiratory distress syndrome (ARDS) in its more severe form, is characterized by an acute exudative phase involving pulmonary edema and inflammation, which leads to severe hypoxemia, often requiring a ventilator. It may occur in patients suffering from SARS-CoV-2 (COVID-19), and continues to cause significant rates of morbidity and mortality.

The mechanisms that govern whether and how these pathophysiological processes occur aren’t well understood, primarily because of the failure for existing preclinical models to completely replicate clinical ALI. Most studies have focused on mechanisms within the acute exudative phase, and very few models look at the later phases of inflammation, resolution, and repair.

This panel discussion focuses on lung and ARDS/multi-organ failure related to COVID-19, and how using in vitro and in vivo models will allow your projects to translate to the clinic more effectively.

 

Webinar Presenters

Mary McElroy Headshot

Mary McElroy, PhD
Associate Director, Respiratory Pharmacology Models
Charles River


Rhiannon Jenkinson Headshot

Rhiannon Jenkinson, PhD
Director of Science, Discovery Services
Charles River


Rana Samadfam Headshot

Rana Samadfam, PhD
Director of Science, Discovery Services
Charles River

 

We are providing digital education options to keep you learning about topics you may be interested in. For more information, visit criver.com/digital-education.